Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?
Moein AlaMahan AlaPublished in: ACS pharmacology & translational science (2021)
Diabetes is accompanied by several complications. Higher prevalence of cancers, cardiovascular diseases, chronic kidney disease (CKD), obesity, osteoporosis, and neurodegenerative diseases has been reported among patients with diabetes. Metformin is the oldest oral antidiabetic drug and can improve coexisting complications of diabetes. Clinical trials and observational studies uncovered that metformin can remarkably prevent or alleviate cardiovascular diseases, obesity, polycystic ovarian syndrome (PCOS), osteoporosis, cancer, periodontitis, neuronal damage and neurodegenerative diseases, inflammation, inflammatory bowel disease (IBD), tuberculosis, and COVID-19. In addition, metformin has been proposed as an antiaging agent. Numerous mechanisms were shown to be involved in the protective effects of metformin. Metformin activates the LKB1/AMPK pathway to interact with several intracellular signaling pathways and molecular mechanisms. The drug modifies the biologic function of NF-κB, PI3K/AKT/mTOR, SIRT1/PGC-1α, NLRP3, ERK, P38 MAPK, Wnt/β-catenin, Nrf2, JNK, and other major molecules in the intracellular signaling network. It also regulates the expression of noncoding RNAs. Thereby, metformin can regulate metabolism, growth, proliferation, inflammation, tumorigenesis, and senescence. Additionally, metformin modulates immune response, autophagy, mitophagy, endoplasmic reticulum (ER) stress, and apoptosis and exerts epigenetic effects. Furthermore, metformin protects against oxidative stress and genomic instability, preserves telomere length, and prevents stem cell exhaustion. In this review, the protective effects of metformin on each disease will be discussed using the results of recent meta-analyses, clinical trials, and observational studies. Thereafter, it will be meticulously explained how metformin reprograms intracellular signaling pathways and alters molecular and cellular interactions to modify the clinical presentations of several diseases.
Keyphrases
- oxidative stress
- signaling pathway
- chronic kidney disease
- cardiovascular disease
- type diabetes
- clinical trial
- stem cells
- immune response
- dna damage
- induced apoptosis
- metabolic syndrome
- risk factors
- cell death
- postmenopausal women
- ischemia reperfusion injury
- pi k akt
- cell proliferation
- epithelial mesenchymal transition
- squamous cell carcinoma
- diabetic rats
- dna methylation
- systematic review
- weight loss
- randomized controlled trial
- gene expression
- endoplasmic reticulum
- end stage renal disease
- mycobacterium tuberculosis
- meta analyses
- endothelial cells
- young adults
- brain injury
- toll like receptor
- bone mineral density
- reactive oxygen species
- rheumatoid arthritis
- peritoneal dialysis
- case report
- body composition
- weight gain
- hiv aids
- dendritic cells
- copy number
- lps induced
- antiretroviral therapy
- phase ii